Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 48-55

  Hansen, Harald S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ceramidase; Ischemia; Memory; N acylethanolamine; N oleoylethanolamine; N palmitoylethanolamine; Neuroprotection; Neurosteroids; Oleoylethanolamide; Potassium channels; PPAR ; Stearoylethanolamide

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANANDAMIDE; CERAMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; N OLEOYLETHANOLAMINE; NEUROSTEROID; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV4.3; STEAROYLETHANOLAMIDE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; AUTOCRINE EFFECT; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; DOPAMINERGIC NERVE CELL; GLIOBLASTOMA; HUMAN; HUNTINGTON CHOREA; MEMORY CONSOLIDATION; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; STEROIDOGENESIS; TUMOR REGRESSION;

EID: 77953724965     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.022     Document Type: Review

References (139)

1. Ahern G.P. Activation of TRPV1 by the satiety factor oleoylethanolamide. J. Biol. Chem. 2003, 278:30429-30434.
2. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 2008, 108:1687-1707.
3. Akk G., Covey D.F., Evers A.S., Steinbach J.H., Zorumski C.F., Mennerick S. The influence of the membrane on neurosteroid actions at GABA(A) receptors. Psychoneuroendocrinology 2009, 34(Suppl. 1):S59-S66.
4. Ambrosini A., Zolese G., Ambrosi S., Ragni L., Tiano L., Littarru G., Bertoli E., Mantero F., Boscaro M., Balercia G. Oleoylethanolamide protects human sperm cells from oxidation stress: studies on cases of idiopathic infertility. Biol. Reprod. 2006, 74:659-665.
5. Amoros I., Barana A., Caballero R., Gomez R., Osuna L., Lillo M.P., Tamargo J., Delpon E. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J. Mol Cell Cardiol 2010, 48:201-210.
6. Artmann A., Petersen G., Hellgren L.I., Boberg J., Skonberg C., Hansen S.H., Hansen H.S. Influence of dietary fatty acids on endocannbinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2008, 1781:200-212.
7. Bachur N.R., Masek K., Melmon K.L., Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissue. J. Biol. Chem. 1965, 240:1019-1024.
8. Barana A., Amoros I., Caballero R., Gomez R., Osuna L., Lillo M.P., Blazquez C., Guzman M., Delpon E., Tamargo J. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc. Res. 2010, 85:56-67.
9. Bazinet R.P., Lee H.J., Felder C.C., Porter A.C., Rapoport S.I., Rosenberger T.A. Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonoylethanolamine) concentration of rat brain. Neurochem. Res. 2006, 30:597-601.
10. Bento-Abreu A., Tabernero A., Medina J.M. Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons. J. Neurochem. 2007, 103:871-881.
11. Berger C., Schmid P.C., Schabitz W.R., Wolf M., Schwab S., Schmid H.H.O. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. J. Neurochem. 2004, 88:1159-1167.
12. Bisogno T., Martire A., Petrosino S., Popoli P., Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 2008, 52:307-313.
13. Bojesen I.N., Hansen H.S. Binding of anandamide to bovine serum albumin. J. Lipid Res. 2003, 44:1790-1794.
14. Bojesen I.N., Hansen H.S. Effect of an unstirred layer on the membrane permeability of anandamide. J. Lipid Res. 2006, 47:561-570.
15. Boland L.M., Drzewiecki M.M., Timoney G., Casey E. Inhibitory effects of polyunsaturated fatty acids on Kv4/KCh1P potassium channels. Am. J. Physiol. Cell. Physiol. 2009, 296:1003-1014.
16. Bonini, J. A. 2002. Methods of identifying compounds that binds to SNORF25 receptors. US Patent 6,468,756.
17. +currents underlie rhythmic activity in hippocampal interneurons. J. Neurosci. 2007, 27:1942-1953.
18. Burkhalter A., Gonchar Y., Mellor R.L., Nerbonne J.M. Differential expression of I(A) channel subunits Kv4.2 and Kv4.3 in mouse visual cortical neurons and synapses. J. Neurosci. 2006, 26:12274-12282.
19. Campolongo P., Roozendaal B., Trezza V., Cuomo V., Astarita G., Fu J., McGaugh J.L., Piomelli D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8027-8031.
20. Carman G.M., Deems R.A., Dennis E.A. Lipid signaling enzymes and surface dilution kinetics. J. Biol. Chem. 1995, 270:18711-18714.
21. Charalampopoulos I., Remboutsika E., Margioris A.N., Gravanis A. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol. Metab. 2008, 19:300-307.
22. Chavez J.A., Knotts T.A., Wang L.P., Li G.B., Dobrowsky R.T., Florant G.L., Summers S.A. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 2003, 278:10297-10303.
23. Chavez J.A., Holland W.L., Bar J., Sandhoff K., Summers S.A. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J. Biol. Chem. 2005, 280:20148-20153.
24. Chen Y., Ginis I., Hallenbeck J.M. The protective effect of ceramide in immature rat brain hypoxia-ischemia involves up-regulation of Bcl-2 and reduction of TUNEL-positive cells. J. Cereb. Blood Flow Metab. 2001, 21:34-40.
25. Chmura S.J., Nodzenski E., Kharbanda S., Pandey P., Quintáns J., Kufe D.W., Weichselbaum R.R. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol. Pharmacol. 2000, 57:792-796.
26. Chu Z.L., Carroll C., Alfonso J., Gutierrez V., He H., Lucman A., Xing C., Sebring K., Zhou J., Wagner B., Unett D., Jones R.M., Behan D.P., Leonard J. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol. Endocrinol. 2010, 24:161-170.
27. Costa B., Comelli F., Bettoni I., Colleoni M., Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008, 139:541-550.
28. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
29. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001, 506:253-256.
30. De Petrocellis L., Bisogno T., Ligresti A., Bifulco M., Melck D., Di Marzo V. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol. 2002, 16:297-302.
31. De Petrocellis L., Chu C.J., Moriello A.S., Kellner J.C., Walker J.M., Di Marzo V. Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br. J. Pharmacol. 2004, 143:251-256.
32. Degn M., Lambertsen K.L., Petersen G., Meldgaard M., Artmann A., Clausen B.H., Hansen S.H., Finsen B., Hansen H.S., Lund T.M. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J. Neurochem. 2007, 103:1907-1916.
33. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
34. Di Filippo M., Pini L.A., Pelliccioli G.P., Calabresi P., Sarchielli P. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:1224-1229.
35. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001, 358:249-255.
36. Eto M., Bennouna J., Hunter O.C., Lotze M.T., Amoscato A.A. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int. J. Urol. 2006, 13:148-156.
37. Ferrer B., Bermudez-Silva F.J., Bilbao A., Alvarez-Jaimes L., Sanchez-Vera I., Giuffrida A., Serrano A., Baixeras E., Khaturia S., Navarro M., Parsons L.H., Piomelli D. Regulation of brain anandamide by acute administration of ethanol. Biochem. J. 2007, 404:97-104.
38. Franklin A., Parmentier-Batteur S., Walter L., Greenberg D.A., Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 2003, 23:7767-7775.
39. Fu J., Gaetani S., Oveisi F., LoVerme J., Serrano A., Rodriguez de Fonseca F., Rosengarth A., Luecke H., Di Ciacomo B., Tarzia G., Piomelli D. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPARα. Nature 2003, 425:90-93.
40. Fu J., Kim J., Oveisi F., Astarita G., Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R45-R50.
41. Furlong S.J., Ridgway N.D., Hoskin D.W. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int. J. Oncol. 2008, 32:537-544.
42. Gaetani S., Kaye W.H., Cuomo V., Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat. Weight Disord. 2008, 13:e42-e46.
43. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
44. Glaser S.T., Kaczocha M. Temporal changes in mouse brain fatty acid amide hydrolase activity. Neuroscience 2009, 163:574-600.
45. Hansen H.H., Ikonomidou C., Bittigau P., Hansen S.H., Hansen H.S. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 2001, 76:39-46.
46. Hansen H.H., Schmid P.C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H.H.O., Fernández-Ruiz J.J., Hansen H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 2001, 78:1415-1427.
47. Hansen H.S., Diep T.A. N-acylethanolamines, anandamide and food intake. Biochem. Pharmacol. 2009, 78:553-580.
48. Hansen H.S., Lauritzen L., Strand A.M., Vinggaard A.M., Frandsen A., Schousboe A. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J. Neurochem. 1997, 69:753-761.
49. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-Acylethanolamines and precursor phospholipids-relation to cell injury. Chem. Phys. Lipids 2000, 108:135-150.
50. Hansen H.S., Moesgaard B., Petersen G., Hansen H.H. Putative neuroprotective actions of N-acyl-ethanolamines. Pharmacol. Ther. 2002, 95:119-126.
51. Hansen H.S., Petersen G., Artmann A., Madsen A.N. Endocannabinoids. Eur. J. Lipid Sci. Technol. 2006, 108:877-889.
52. Hansen S.L., Nielsen A.H., Knudsen K.E., Artmann A., Petersen G., Kristiansen U., Hansen S.H., Hansen H.S. Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus. Neurochem. Int. 2009, 54:199-204.
53. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 1993, 36:3032-3034.
54. Haversen L., Danielsson K.N., Fogelstrand L., Wiklund O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Artherpsclerosis 2009, 202:382-392.
55. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
56. Ho W.S., Barrett D.A., Randall M.D. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155:837-846.
57. Hostetler H.A., Petrescu A.D., Kier A.B., Schroeder F. Peroxisome proliferator-activated receptor α interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem. 2005, 280:18667-18682.
58. Houben E., Uchida Y., Nieuwenhuizen W.F., De Paepe K., Vanhaecke T., Holleran W.M., Rogiers V. Kinetic characteristics of acidic and alkaline ceramidase in human epidermis. Skin Pharmacol. Physiol. 2007, 20:187-194.
59. Hu S.S., Bradshaw H.B., Benton V.M., Chen J.S., Huang S.M., Minassi A., Bisogno T., Masuda K., Tan B., Roskoski R., Cravatt B.F., Di Marzo V., Walker J.M. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:291-301.
60. Hwang, J., Adamson, C., Butler, D., Janero, D.R., Makriyannis, A., Bahr, B.A., 2010. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci. 86, 615-623.
61. Jonsson K.O., Vandevoorde S., Lambert D.M., Tiger G., Fowler C.J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 2001, 133:1263-1275.
62. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6375-6380.
63. Karanian D.A., Karim S.L., Wood J.T., Williams J.S., Lin S., Makriyannis A., Bahr B.A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J. Pharmacol. Exp. Ther. 2007, 322:1059-1066.
64. Khairy H., Adjei G., Alle-Redpath K., Scott R.H. Actions of ethanolamine on cultured sensory neurones from neonatal rats. Neurosci. Lett. 2010, 468:326-329.
65. Kingsley P.J., Marnett L.J. Analysis of endocannabinoids, their congeners and COX-2 metabolites. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:2746-2754.
66. Koethe D., Schreiber D., Giuffrida A., Mauss C., Faulhaber J., Heydenreich B., Hellmich M., Graf R., Klosterkotter J., Piomelli D., Leweke F.M. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J. Neural. Transm. 2009, 206:551-560.
67. Kuehl F.A., Jacob T.A., Ganley O.H., Ormond R.E., Meisinger M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Oil Chem. Soc. 1957, 79:5577-5578.
68. Lambert D.M., Vandevoorde S., Diependaele G., Govaerts S.J., Robert A.R. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001, 42:321-327.
69. Leung D., Saghatelian A., Simon G.M., Cravatt B.F. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006, 45:4720-4726.
70. Llacuna L., Mari M., Garcia-Ruiz C., Fernandez-Checa J.C., Morales A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 2006, 44:561-572.
71. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-a mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005, 67:15-19.
72. Lo Verme J., Gaetani S., Fu J., Oveisi F., Burton K., Piomelli D. Regulation of food intake by oleoylethanolamide. Cell. Mol. Life Sci. 2005, 62:708-716.
73. Lo Verme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 2006, 319:1051-1061.
74. Loria F., Petrosino S., Mestre L., Spagnolo A., Correa F., Hernangomez M., Guaza C., Di Marzo V., Docagne F. Study off the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008, 28:633-641.
75. Maag H. Fatty acid derivatives: important surfactants for household, cosmetic and industrial purposes. J. Am. Oil Chem. Soc. 1984, 61:259-267.
76. Maccarrone M., Pauselli R., Di Rienzo M., Finazzi-Agrò A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J. 2002, 366:137-144.
77. Maccarrone M., Cartoni A., Parolaro D., Margonelli A., Massi P., Bari M., Battista N., Finazzi-Agrò A. Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Mol. Cell. Neurosci. 2002, 21:126-140.
78. Mazzola C., Medalie J., Scherma M., Panlilio L.V., Solinas M., Tanda G., Drago F., Cadet J.L., Goldberg S.R., Yasar S. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn. Mem. 2009, 16:332-337.
79. McCue J.M., Driscoll W.J., Mueller G.P. In vitro synthesis of arachidonoyl amino acids by cytochrome c. Prostaglandins Other Lipid Mediat. 2009, 90:42-48.
80. McDonald G.R., Hudsen A.L., Dunn S.M., You H., Baker G.B., Whittal R.M., Martin J.W., Jha A., Edmondson D.E., Holt A. Bioactive contaminants leach from disposable laboratory plasticware. Science 2008, 322:917.
81. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature 1997, 389:25-26.
82. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., Pistis M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J. Neurosci. 2008, 28:13985-13994.
83. Mitchell E.A., Herd M.B., Gunn B.G., Lambert J.J., Belelli D. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem. Int. 2008, 52:588-595.
84. 31P NMR study. J. Lipid Res. 1999, 40:515-521.
85. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wölfel B., Dodt H.U., Zieglgänsberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
86. Morales A., Paris R., Villanueva A., Llacuna L., Garcia-Ruiz C., Fernandez-Checa J.C. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2007, 26:905-916.
87. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
88. Movahed P., Jönsson B.A.G., Birnir B., Wingstrand J.A., Jorgensen T.D., Ermund A., Sterner O., Zygmunt P.M., Högestätt E.D. Endogenous unsaturated C18N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J. Biol. Chem. 2005, 280:38496-38504.
89. Mullen K.M., Rozycka M., Rus H., Hu L., Cudrici C., Zafranskaia E., Pennington M.W., Johns D.C., Judge S.I., Calabresi P.A. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann. Neurol. 2006, 60:118-127.
90. Murillo-Rodriguez E., Désarnaud F., Prospéro-Garcia O. Dirunal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci. 2006, 79:30-37.
91. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K.L., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 1999, 19:2987-2995.
92. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., Evans R.M. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
93. Nomura D.K., Blankman J.L., Simon G.M., Fujioka K., Issa R.S., Ward A.M., Cravatt B.F., Casida J.E. Activation of the endocannabinoid system by organophosphorus nerve agents. Nat. Chem. Biol. 2008, 4:373-378.
94. Oddi S., Fezza F., Pasquariello N., D'Agostino A., Catanzaro G., De Simone C., Rapino C., Finazzi-Agro A., Maccarrone M. Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem. Biol. 2009, 16:624-632.
95. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 2004, 279:5298-5305.
96. Ordway R.W., Walsh J.V., Singer J.J. Arachidonic acid and other fatty acids directly activated potassium channels in smooth muscle cells. Science 1989, 244:1176-1178.
97. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., Jackson H.C., Procter M.J., Rasamison C.M., Tang-Christensen M., Widdowson P.S., Williams G.M., Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3:167-175.
98. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol. Ther. 2006, 111:114-144.
99. Pannasch U., Farber K., Nolte C., Blonski M., Yan C.S., Messing A., Kettenmann H. The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. Mol. Cell Neurosci. 2006, 33:401-411.
100. Petersen G., Moesgaard B., Schmid P.C., Schmid H.H.O., Broholm H., Kosteljanetz M., Hansen H.S. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumor brain tissue. J. Neurochem. 2005, 93:299-309.
101. Petersen G., Pedersen A.H., Pickering D.S., Begtrup M., Hansen H.S. Effect of synthetic and natural phospholipids on N-acylphosphatidylethanolamine-hydrolyzing phospholipase D activity. Chem. Phys. Lipids 2009, 162:53-61.
102. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12:21-38.
103. Preussat K., Beetz C., Schrey M., Kraft R., Wolfl S., Kalff R., Patt S. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas. Neurosci. Lett. 2003, 346:33-36.
104. Radin N.S. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem. J. 2003, 371:243-256.
105. Riboni L., Campanella R., Bassi R., Villani R., Gaini S.M., Martinelli-Boneschi F., Viani P., Tettamanti G. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002, 39:105-113.
106. Riserus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., Fang Z., Hegde P., Richards D., Sarov-Blat L., Strum J.C., Basu S., Cheeseman J., Fielding B.A., Humphreys S.M., Danoff T., Moore N.R., Murgatroyd P., O'Rahilly S., Sutton P., Willson T., Hassall D., Frayn K.N., Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
107. Rubio M., McHugh D., Fernandez-Ruiz J., Bradshaw H., Walker J.M. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci. Lett. 2007, 421:270-274.
108. Sarchielli P., Pini L.A., Coppola F., Rossi C., Baldi A., Mancini M.L., Calabresi P. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 2007, 32:1384-1390.
109. Sasso O., La R.G., Vitiello S., Russo R., D'Agostino G., Iacono A., Russo E., Citraro R., Cuzzocrea S., Piazza P.V., De S.G., Meli R., Calignano A. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice involvement of allopregnanolone biosynthesis. Eur. Neuropsychopharmacol. 2010, 20:195-206.
110. Schabitz W.R., Giuffrida A., Berger C., Aschoff A., Schwaninger M., Schwab S., Piomelli D. Release of fatty acid amides in a patient with hemispheric stroke-a microdialysis study. Stroke 2002, 33:2112-2114.
111. Schmid P.C., Reddy P.V., Natarajan V., Schmid H.H.O. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 1983, 258:9302-9306.
112. Schmid H.H.O., Schmid P.C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 1990, 29:1-43.
113. Schomacher M., Muller H.D., Sommer C., Schwab S., Schabitz W.R. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res. 2008, 1240:213-220.
114. Sheerin A.H., Zhang T., Saucier D.M., Corcoran M.E. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia 2004, 45:1184-1188.
115. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 1997, 40:659-667.
116. Simon G.M., Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl-ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem. 2006, 281:26465-26472.
117. Simon G.M., Cravatt B.F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J. Biol. Chem. 2008, 283:9341-9349.
118. Skaper S.D., Facci L., Romanello S., Leon A. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J. Neurochem. 1996, 66:1157-1166.
119. Smart D., Jonsson K.O., Vandevoorde S., Lambert D.M., Fowler C.J. 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 2002, 136:452-458.
120. Spinedi A., Di Bartolomeo S., Piacentini M. N-Oleoylethanolamine inhibits glucosylation of natural ceramides in CHP-100 neuroepithelioma cells: possible implications for apoptosis. Biochem. Biophys. Res. Commun. 1999, 255:456-459.
121. Stoddart L.A., Smith N.J., Milligan G. International Union of Pharmacology LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharm. Rev. 2008, 60:405-417.
122. Suardiaz M., Estivill-Torrus G., Goicoechea C., Bilbao A., Rodriguez de Fonseca F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 2007, 133:99-110.
123. Sugita M., Willians M., Dulaney J.T., Moser H.W. Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim. Biophys. Acta 1975, 398:125-131.
124. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor-structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 1999, 274:2794-2801.
125. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., Suhara Y., Takayama H., Waku K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor-comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 2000, 275:605-612.
126. 2 and lysophospholipase D. Biochem. J. 2004, 380:749-756.
127. Sun Y., Alexander S.P., Kendall D.A., Bennett A.J. Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 2006, 34:1095-1097.
128. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., Kendall D.A., Bennett A.J. Cannabinoid activation of PPARalpha; a novel neuroprotective mechanism. Br. J. Pharmacol. 2007, 152:734-743.
129. Tan B., O'Dell D.K., Yu Y.W., Monn M.F., Hughes H.V., Burstein S., Walker J.M. Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J. Lipid Res. 2010, 51:112-119.
130. Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P., Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 2001, 21:1104-1109.
131. Tsuboi K., Takezaki N., Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem. Biodivers. 2007, 4:1914-1925.
132. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 1995, 270:23823-23827.
133. Wang J., Ueda N. Biology of the endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 2009, 89:112-119.
134. Wang X., Miyares R.L., Ahern G.P. Oleoylethanolamide excites vagal sensory neurons, induces viceral pain and reduces food intake via TRPV1. J. Physiol. (Lond.) 2005, 564:541-547.
135. Wasilewski M., Wojtczak L. Effects of N-acylethanolamines on the respiratory chain and production of reactive oxygen species in heart mitochondria. FEBS Lett. 2005, 579:4724-4728.
136. Wasilewski M., Wieckowski M.R., Dymkowska D., Wojtczak L. Effects of N-acylethanolamines on mitochondrial energetics and permeability transition. Biochim. Biophys. Acta Bio-Energetics 2004, 1657:151-163.
137. Wiesner D.A., Dawson G. Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway. J. Neurochem. 1996, 66:1418-1425.
138. Zolese G., Falcioni G., Bertoli E., Galeazzi R., Wozniak M., Wypych Z., Gratton E., Ambrosini A. Steady-state and time resolved fluorescence of albumins interacting with N-oleylethanolamine, a component of the endogenous N-acylethanolamines. Proteins 2000, 40:39-48.
139. Zolese G., Bacchetti T., Masciangelo S., Ragni L., Ambrosi S., Ambrosini A., Marini M., Ferretti G. Effect of acylethanolamides on lipid peroxidation and paraoxonase activity. BioFactors 2008, 33:201-209.